Cardiovascular diseases remain the leading cause of death worldwide and generate healthcare costs in the hundreds of billions each year in Europe alone. Despite this burden, drug development has largely stagnated. One major challenge is the limited reliability of animal models, which differ significantly from the human heart and therefore provide only limited predictive value.
The myotwin Approach
myotwin has developed a proprietary organoid and screening platform that realistically replicates human heart muscle tissue. This technology enables precise measurement of key parameters such as tissue stiffness and excitation–contraction coupling – critical markers that have so far been difficult to capture in preclinical research.
The Founders
myotwin was founded by Andreas Meyer-Borgstädt, Dr.-Ing. Jan Pietras, and Dr. rer. nat. Hendrik Windel. Together, they combine expertise in biotechnology, artificial intelligence, and entrepreneurship to advance the development of a digital heart twin and open new paths for diagnostics and therapy.
“Our mission is to better understand the heart and accelerate the development of novel therapies. Ultimately, we want patients around the world to gain faster access to life-saving medications,” says co-founder and CEO Dr.-Ing. Jan Pietras.
Spin-off from University Medical Center Göttingen
myotwin GmbH is a spin-off from the University Medical Center Göttingen and builds on extensive research conducted within the EXIST Transfer of Research program.